Acutus Medical Inc. · OTC:AFIB
Acutus Medical — Investor Presentation (January 2021)
23 slides from Acutus Medical's investor presentation, Jan 13, 2021
Slide 1: Guided Ablation Therapy for Cardiac Arrhythmias
Guided Ablation Therapy for Cardiac Arrhythmias Exhibit 99.2
Slide 2: Legal Disclaimer
Legal Disclaimer 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availabi
Slide 3: Investment Highlights
Investment Highlights 3 1 2 3 4 5 6 7 8 Paradigm-shifting ablation guidance technology, future in electroporation Pure-play electrophysiology company / Comprehensive, differentiated portfolio Large, growing and underpenetrated market Efficient commercial model and access to labs Global presence via
Slide 4: Global Electrophysiology ("EP") Ablation Market
Global Electrophysiology (“EP”) Ablation Market ~$5.7 Billion ~1.1 million ablation procedures Global 2019 EP ablation supplies market (1) (2) ~13% Annual growth rate of ablation procedures worldwide since 2016 (1) Progressive disease, function of aging Western lifestyle Increasing utilization of se
Slide 5: Attractive ~$5.7bn market for electrophysiology products
5 Attractive ~$5.7bn market for electrophysiology products that has grown ~13% annually since 2016 (1) (2) Based on internal Company estimates Market size reflects disposable products Difficult to map Long and unpredictable procedures (2-6hrs) Patients often need a repeat procedure Current market ch
Slide 6: Efficient, Effective Treatment of Complex Arrhythmias Remains Elusive
Efficient, Effective Treatment of Complex Arrhythmias Remains Elusive Persistent Atrial Fibrillation Example 6 High therapy failure rates ~50% of ablations for Persistent AF result in recurrence within 12 months (2) High cost of retreatment procedures High cost of hospitalization from complications
Slide 7: Our Vision – Lead the Field of Guided Ablation Therapy
Our Vision – Lead the Field of Guided Ablation Therapy for Cardiac Arrhythmias Comprehensive Suite of Highly Differentiated Products for EP 7 * Partnerships Ϯ Development, not currently marketed
Slide 8: Acutus' Guided Ablation Therapy Platform
Acutus’ Guided Ablation Therapy Platform Whole Heart Chamber Mapping in Under 3 Minutes 8
Slide 9: Whole-Chamber Views of Complex Rhythms in Under Minutes
Whole-Chamber Views of Complex Rhythms in Under 3 Minutes Full Function System -- Individualized for Physicians and Patients 9 Ultrasound Anatomy Vein Build Tool SuperMap Automated Processing Isochronal Local Activation Time Map Propagation History Map Conventional Contact Map
Slide 10: Why Is the Market Less Than 5% Penetrated?
Why Is the Market Less Than 5% Penetrated? (1) How and Where Acutus Can Add Value / Solve Problems 10 Atrial Fibrillation Supraventricular Tachycardias (1) Based on internal Company estimates (2) AcQMap catheter is not currently indicated for use in the ventricle Percentages above based on company e
Slide 11: Acutus Comparative Outcomes for Persistent AF
Acutus Comparative Outcomes for Persistent AF* Meaningful Clinical Improvement vs. Stagnant Standard of Care 11 UNCOVER AF (AcQMap): We believe fundamentally different mapping approach & therapy strategy (non-contact mapping & map/treat/re-map strategy) leads to improved success rates 1: Willems et
Slide 12: Acutus in Atrial Tachycardia: Safe, Fast and Feasible
Acutus in Atrial Tachycardia ”Safe, Fast and Feasible” Atrial tachycardias (AT) can be observed following up to 25%[1-5] of AF ablation procedures Prior studies have reported average procedure times of 4-7 hours6 in follow-up ablation procedures to remedy these tachycardias In a “first use” study pu
Slide 13: Our Comprehensive Portfolio and Partnerships
Our Comprehensive Portfolio and Partnerships 13 * Partnerships Ϯ Development, not currently marketed
Slide 14: Comprehensive, Differentiated Therapy Portfolio
Comprehensive, Differentiated Therapy Portfolio AcQBlate Force-Sensing Ablation Catheter and System First and only commercially available irrigated force-sensing catheter in the market featuring a Gold Tip Electrode 14 / / Qubic RF (1) Qiona Pump (1) AcQBlate Gold Flutter AcQBlate Gold EvenTemp All
Slide 15: Innovation Pipeline: Pulsed Field Ablation
15 Innovation Pipeline: Pulsed Field Ablation Pulsed Field Ablation is a promising new energy modality under investigation for cardiac ablations Conduction blocked at PFA Line This presentation may include products not yet for sale in the U.S. What is it? Sequence of very short duration high voltage
Slide 16: Broad, Differentiated Left Heart Access Product Line
Broad, Differentiated Left Heart Access Product Line 16 Patient Safety & Physician Confidence Spring-tensioned safety needle, reduces risk to patient as well as staff Length-matched needle to introducer locks together for control & ease of use Enhanced Procedural Efficiency Reduced need for wire exc
Slide 17: Acutus / Biotronik International Alliance for EP
Acutus / Biotronik International Alliance for EP 17 Global Reach in Developed Markets Acutus to sell its core mapping, ablation, and accessory products and private (Acutus) labeled products manufactured by Biotronik Same as above, but private (Acutus) labeled products manufactured by Biotronik distr
Slide 18: Stereotaxis Robot Integration and Partnership
Acutus’ guided ablation therapy platform fully integrated with the Stereotaxis EP robot Synchronized anatomy rotation between robotics and imaging system Allows precise targeting of pulmonary vein and non-pulmonary vein triggers Stereotaxis® Robot Integration and Partnership 18
Slide 19: Innovative Health Partnership
Have a favorite? Go ahead and use it! Innovative Health® Partnership 19 This presentation may include products not for sale in the U.S. This presentation contains products that are not manufactured by Acutus Medical Acutus has partnered with Innovative Health to bring 28+ reprocessed catheters to ou
Slide 20: Pure Play, Stand-Alone EP Company
Pure Play, Stand-Alone EP Company Approved, highly differentiated products in many categories 20 (1) Anticipated timing (Future availability timelines are estimates subject to risks and uncertainties. See “Risk Factors” in the public filings.)
Slide 21: Model and Key Revenue Drivers
Model and Key Revenue Drivers Up to $10K (1) revenue potential for disposables / procedure 21 X X (1) Based on internal Company estimates
Slide 22: Continue installed base build
Continue installed base build Drive adoption and incremental revenue per case via: Successful product launches of additional/improved accessory products. Launches planned for first half of 2021 include: Force Sensing Ablation system in (CE markets only) Improved patch kits Expanded left heart access
Slide 23: Thank you for your time!
Thank you for your time! Acutus Medical, Inc. CAL NASDAQ: AFIB
Acutus Medical — Investor Presentation (January 2021) on 6ix